The effectiveness osimertinib in treating non-small-cell lung cancer
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A. |
Posted on August 9th, 2023
|
The current treatment regimen for non-small-cell lung cancer included a surgical resection of the tumor followed by adjuvant chemotherapy. However, the latter long-term treatment had low efficacy in preventing recurrence and death, especially in patients with mutation to the epidermal growth factor receptor (EGFR). Osimertinib is an agent that can bind to and inhibit both wild type and mutant EGFR. AstraZeneca had sponsored a study to assess the effectiveness of Osimertinib, and the finding had been published in the New England Journal of Medicine.
The phase 3 clinical trial included 682 patients who were diagnosed with either stage IB, II, or IIIa of non-small-cell lung cancer and have had the tumor surgically resected. These patients were randomly assigned to receive either placebo or oral osimertinib at a dose of 80 mg per day. The treatment was continued for 3 years and its effectiveness was monitored for an additional 2 years. Over 5 years, the researchers concluded that osimertinib helped reduce the risk of death by 56% in patients with stage I tumor and 51% in patients with more advanced disease. Safety assessment did not find any significant enhanced risk of adverse events caused by osimertinib.
The phase 3 clinical trial included 682 patients who were diagnosed with either stage IB, II, or IIIa of non-small-cell lung cancer and have had the tumor surgically resected. These patients were randomly assigned to receive either placebo or oral osimertinib at a dose of 80 mg per day. The treatment was continued for 3 years and its effectiveness was monitored for an additional 2 years. Over 5 years, the researchers concluded that osimertinib helped reduce the risk of death by 56% in patients with stage I tumor and 51% in patients with more advanced disease. Safety assessment did not find any significant enhanced risk of adverse events caused by osimertinib.